Showing results (1611-1620 of 1,735) with videos related to
Sort By:
Pageof 174
CNS Spectrums|January 19, 2021
Divergence of dose-response with asenapine: a cluster analysis of randomized, double-blind, and placebo control studyYoshiteru Takekita, Shuichi Hiraoka, Yasuhiro Iwama, et al.CNS Spectrums|October 1, 2019
Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal ActivityStephen M StahlCNS Spectrums|September 13, 2019
Pathophysiologic mechanisms, neuroimaging and treatment in wake-up strokeMohamed Elfil, Mohamed Eldokmak, Alireza Baratloo, et al.CNS Spectrums|September 5, 2019
Keeping up with the clinical advances: tardive dyskinesiaMazen T Elkurd, Laxman BahrooCNS Spectrums|February 10, 2021
Pivotal clinical trial enrollment of Blacks in multiple sclerosis or neuromyelitis spectrum disorder: when will we achieve parity?Jagannadha Avasarala, Phenu Zachariah, Breck TurnerCNS Spectrums|February 5, 2021
Pharmacological interventions to reduce violence in patients with schizophrenia in forensic psychiatryAndreas Reisegger, Rudolf Slamanig, Hildegard Winkler, et al.CNS Spectrums|December 23, 2016
Augmentation of phenelzine with aripiprazole and quetiapine in a treatment-resistant patient with psychotic unipolar depression: case report and literature reviewJonathan M Meyer, Michael A Cummings, George ProctorCNS Spectrums|December 23, 2016
Treating mixed mania/hypomania: a review and synthesis of the evidenceMinoru TakeshimaCNS Spectrums|November 9, 2016
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active controlRonald Landbloom, Mary Mackle, Xiao Wu, et al.CNS Spectrums|November 24, 2018
Cognitive impairment in major depressive disorderZihang Pan, Caroline Park, Elisa Brietzke, et al.Pageof 174